CLINICAL TRIALS PROFILE FOR VIDAZA
✉ Email this page to a colleague
All Clinical Trials for VIDAZA
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00101179 ↗ | MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia | Completed | National Cancer Institute (NCI) | Phase 1 | 2004-11-03 | MS-275 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving MS-275 together with azacitidine may kill more cancer cells. This phase I trial is studying the side effects and best dose of MS-275 when given together with azacitidine in treating patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, or acute myeloid leukemia. |
| NCT00118287 ↗ | Azacitidine and Etanercept in Treating Patients With Myelodysplastic Syndromes | Completed | National Cancer Institute (NCI) | Phase 1/Phase 2 | 2005-04-01 | This phase I/II trial studies how well giving azacitidine together with etanercept works in treating patients with myelodysplastic syndromes (MDS). Drugs used in chemotherapy, such as azacitidine, works in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Chemoprotective drugs, such as etanercept, may protect normal cells from the side effects of chemotherapy |
| NCT00118287 ↗ | Azacitidine and Etanercept in Treating Patients With Myelodysplastic Syndromes | Completed | Fred Hutchinson Cancer Research Center | Phase 1/Phase 2 | 2005-04-01 | This phase I/II trial studies how well giving azacitidine together with etanercept works in treating patients with myelodysplastic syndromes (MDS). Drugs used in chemotherapy, such as azacitidine, works in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Chemoprotective drugs, such as etanercept, may protect normal cells from the side effects of chemotherapy |
| NCT00118287 ↗ | Azacitidine and Etanercept in Treating Patients With Myelodysplastic Syndromes | Completed | Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium | Phase 1/Phase 2 | 2005-04-01 | This phase I/II trial studies how well giving azacitidine together with etanercept works in treating patients with myelodysplastic syndromes (MDS). Drugs used in chemotherapy, such as azacitidine, works in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Chemoprotective drugs, such as etanercept, may protect normal cells from the side effects of chemotherapy |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for VIDAZA
Condition Name
Clinical Trial Locations for VIDAZA
Trials by Country
Clinical Trial Progress for VIDAZA
Clinical Trial Phase
Clinical Trial Sponsors for VIDAZA
Sponsor Name
